现代检验医学杂志2011，Vol.26Issue(4)：31-33,3.DOI:10.3969/j.issn.1671-7414.2011.04.010
沙利度胺联合化疗治疗急性白血病对血浆VEGF及其受体水平的影响
Influence of Plasma Vascular Endothelial Growth Factor and Its Receptor Level in Acute Leukemia before and after Treatment by Thalidomide Combined with Chemotherapy
摘要
Abstract
Objective To observe on the clinical effect and the influence of the level of plasma vascular endothelial growth factor and its receptor in acute leukemia before and after treatment by thalidomide combined with chemotherapy. Methods 36 cases of acute leukemia patients were randomly divided into experimental group and control group by 18 cases each.Each group was treated with conventional chemotherapy in the standard-dose meanwhile in the experimental group additional thalidomide 100 mg/d were taken orally for long-term. Before treatment and 8 weeks after treatment,plasma were collected for the detection of VEGF, VEGFR content by double antibody sandwich enzyme-linked immunosorbent assay (ELISA). Results The ratio of effective were 88. 9％ and 77. 8％ respectively in experimental group and control group,the difference was statistically significant (x2 = 4. 103.P＜0. 05). The level of plasma VEGF (389. 78± 249. 94 pg/ml,318. 54±125. 78 pg/ml) of experimental group and control group before treatment was statistically significant (t = 3. 141,t= 3. 024, P ＜ 0. 01 , P＜ 0. 01) compared with healthy group (132. 91± 26. 66 pg/ml) respectively. The level of plasma VEGF of those groups after treatment (211. 74±36. 72 pg/ml,288. 02 ± 31. 77 pg/ml) was statistically significant (t=2. 413, t = 2. 324, P＜ 0. 05, P ＜ 0. 05) compared with healthy group respectively. The difference of the level of plasma VEGF of experimental group and control group before treatment was not statistically significant (t= 1. 384,P＞0. 05). The difference of the level of plasma VEGF of experimental group and control group after treatment was statistically significant (t = 2. 793,P＜0. 05). The level of plasma VEGFR (2 490. 75±1 695. 9 pg/ml,2 322. 78±1 105. 87 pg/ml)of experimental group and control group before treatment was statistically significant (t=2. 914,t= 2. 783,P＜0.01,P＜0. 01) compared with healthy group (1 134. 98±378. 45 pg/ml) respectively. The level of plasma VEGFR of those groups after treatment (1 359. 71±390. 24 pg/ml,1 753. 89 ± 337. 04 pg/ml) was statistically significant (t= 2. 572,t= 2. 447,P＜0. 05,P＜0. 05)compared with healthy group respectively. The difference of the level of plasma VEGFR of experimental group and control group before treatment was not statistically significant (t=1. 276,P＞0. 05). The difference of the level of plasma VEGFR of expenmental group and control group after treatment was statistically significant (t = 2. 486 , P＜ 0. 05). The level of plasma VEGF and VEGFR were correlated with clinical efficacy (r=0. 613,r=0. 575,P＜0. 05). Conclusion Thalidomide combined with chemotherapy can improve the remission rate of patients with acute leukemia,and its mechanism may be conduced through inhibiting the plasma levels of VEGF and its receptor expression,then take effect on anti-leukemia.关键词
急性白血病/沙利度胺/血管内皮生长因子Key words
acute leukemia/thalidomide / vascular endothelial growth factor分类
医药卫生引用本文复制引用
翟欣辉,魏绪仓,王一,连小赟,赵园,张玎,苗玉迪..沙利度胺联合化疗治疗急性白血病对血浆VEGF及其受体水平的影响[J].现代检验医学杂志,2011,26(4):31-33,3.基金项目
陕西省科技攻关基金资助项目(2010K14-02-14). （2010K14-02-14）
